Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Interstitial Cystitis (Painful Bladder Syndrome) Pipeline Review 2016: Analysis of 9 Companies & 15 Molecules - Research and Markets

Research and Markets
Posted on: 20 Oct 16

Research and Markets has announced the addition of the "Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H2 2016" report to their offering.

Interstitial Cystitis (Painful Bladder Syndrome) pipeline therapeutics constitutes close to 15 molecules, out of which approximately 14 molecules are developed by Companies and the remaining by the Universities/Institutes. The molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 1, 4 and 1, respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Interstitial Cystitis - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Interstitial Cystitis Overview
  3. Therapeutics Development
  4. Pipeline Products for Interstitial Cystitis - Overview
  5. Pipeline Products for Interstitial Cystitis - Comparative Analysis
  6. Interstitial Cystitis - Therapeutics under Development by Companies
  7. Interstitial Cystitis - Therapeutics under Investigation by Universities/Institutes
  8. Interstitial Cystitis Products Glance
  9. Late-Stage Products
  10. Clinical-Stage Products
  11. Early-Stage Products
  12. Interstitial Cystitis - Products under Development by Companies
  13. Interstitial Cystitis - Products under Investigation by Universities/Institutes
  14. Interstitial Cystitis - Companies Involved in Therapeutics Development
  • Allergan Plc
  • Aquinox Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • Kytogenics Pharmaceuticals Inc.
  • Lipella Pharmaceuticals Inc.
  • MediPost Co. Ltd.
  • UCB S.A.
  • Urigen Pharmaceuticals Inc.
  • UroGen Pharmaceuticals Ltd.

For more information about this report visit

View source version on

Business Wire

Last updated on: 20/10/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.